Research Use Only. Peptides Lab UK supplies research-grade materials for in-vitro laboratory research only. Nothing on this page is medical advice or an instruction for human or animal use, and no product sold on this website is a medicine.
What is AOD-9604?
AOD-9604 is a modified synthetic fragment corresponding to the C-terminal region (residues 177–191) of human growth hormone, with an additional N-terminal tyrosine. It was developed as a research compound to study lipolytic activity attributed to this region of growth hormone, and it is not an authorised medicine in the UK.
Published research
A study in obese mice compared chronic administration of growth hormone with a modified C-terminal fragment and reported increased fat oxidation in the animals. A 2004 drug-development review summarised the compound’s programme. AOD-9604 is also of interest in anti-doping science, where mass-spectrometry methods for its detection and in-vitro metabolism have been published. Recent reviews of unapproved peptides note limited high-quality human evidence.[1,2,3,4]
Limitations of the evidence
Much of the available literature is preclinical (cell and animal models) or comes from small numbers of research groups. Findings in defined experimental systems cannot be extrapolated to other settings, and this page does not provide dosing, administration or human-use information.
Laboratory handling and storage
Lyophilised peptides are generally stored sealed, protected from light and moisture, at low temperature as specified on the certificate of analysis. Once reconstituted for in-vitro work, solutions are typically kept refrigerated and used within a validated stability window. Researchers should follow their institution’s procedures and the batch documentation (HPLC purity and mass-spectrometry identity) supplied with each lot.
UK regulatory status
In the UK, medicines are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). Research-grade compounds sold by Peptides Lab UK are supplied strictly for laboratory research; they are not medicinal products, are not manufactured to medicinal GMP standards and must not be used in humans or animals.
Related research pages
References
- Heffernan MA et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001; 25(10):1442-9. doi:10.1038/sj.ijo.0801740 PMID: 11673763.
- Wilding J et al. AOD-9604 Metabolic. Curr Opin Investig Drugs. 2004; 5(4):436-40. PMID: 15134286.
- Cox HD et al. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015; 7(1):31-8. doi:10.1002/dta.1715 PMID: 25208511.
- Mendias CL et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026; 56(8):1921-1935. doi:10.1007/s40279-026-02437-0 PMID: 41966639.
Disclaimer: All products sold by Peptides Lab UK are for laboratory research use only. Not for human or veterinary use, not for consumption, and not intended to diagnose, treat, cure or prevent any disease. This page is an educational literature summary and is not medical advice.
